Movatterモバイル変換


[0]ホーム

URL:


US20140248314A1 - Pre-fusion rsv f antigens - Google Patents

Pre-fusion rsv f antigens
Download PDF

Info

Publication number
US20140248314A1
US20140248314A1US14/117,588US201214117588AUS2014248314A1US 20140248314 A1US20140248314 A1US 20140248314A1US 201214117588 AUS201214117588 AUS 201214117588AUS 2014248314 A1US2014248314 A1US 2014248314A1
Authority
US
United States
Prior art keywords
rsv
fusion
protein
polypeptide
mab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/117,588
Inventor
Kurt Swanson
Andrea Carfi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=46124783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20140248314(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AGfiledCriticalNovartis AG
Priority to US14/117,588priorityCriticalpatent/US20140248314A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC.reassignmentNOVARTIS VACCINES AND DIAGNOSTICS, INC.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: CARFI, ANDREA, SWANSON, KURT
Assigned to NOVARTIS AGreassignmentNOVARTIS AGASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Publication of US20140248314A1publicationCriticalpatent/US20140248314A1/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS SAreassignmentGLAXOSMITHKLINE BIOLOGICALS SAASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: NOVARTIS AG
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

Description

Claims (30)

US14/117,5882011-05-132012-05-14Pre-fusion rsv f antigensAbandonedUS20140248314A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US14/117,588US20140248314A1 (en)2011-05-132012-05-14Pre-fusion rsv f antigens

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201161486005P2011-05-132011-05-13
US14/117,588US20140248314A1 (en)2011-05-132012-05-14Pre-fusion rsv f antigens
PCT/US2012/037773WO2012158613A1 (en)2011-05-132012-05-14Pre-fusion rsv f antigens

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/US2012/037773A-371-Of-InternationalWO2012158613A1 (en)2011-05-132012-05-14Pre-fusion rsv f antigens

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US15/789,074ContinuationUS20180237476A1 (en)2011-05-132017-10-20Pre-fusion rsv f antigens

Publications (1)

Publication NumberPublication Date
US20140248314A1true US20140248314A1 (en)2014-09-04

Family

ID=46124783

Family Applications (8)

Application NumberTitlePriority DateFiling Date
US14/117,588AbandonedUS20140248314A1 (en)2011-05-132012-05-14Pre-fusion rsv f antigens
US15/789,074AbandonedUS20180237476A1 (en)2011-05-132017-10-20Pre-fusion rsv f antigens
US17/314,649AbandonedUS20210269489A1 (en)2011-05-132021-05-07Pre-fusion rsv f antigens
US17/848,230Active2032-07-09US12139512B2 (en)2011-05-132022-06-23Pre-fusion RSV F antigens
US17/848,247PendingUS20220332767A1 (en)2011-05-132022-06-23Pre-fusion rsv f antigens
US18/308,583AbandonedUS20230287056A1 (en)2011-05-132023-04-27Pre-fusion rsv f antigens
US18/596,426AbandonedUS20240239845A1 (en)2011-05-132024-03-05Pre-fusion rsv f antigens
US18/895,059PendingUS20250042951A1 (en)2011-05-132024-09-24Pre-fusion rsv f antigens

Family Applications After (7)

Application NumberTitlePriority DateFiling Date
US15/789,074AbandonedUS20180237476A1 (en)2011-05-132017-10-20Pre-fusion rsv f antigens
US17/314,649AbandonedUS20210269489A1 (en)2011-05-132021-05-07Pre-fusion rsv f antigens
US17/848,230Active2032-07-09US12139512B2 (en)2011-05-132022-06-23Pre-fusion RSV F antigens
US17/848,247PendingUS20220332767A1 (en)2011-05-132022-06-23Pre-fusion rsv f antigens
US18/308,583AbandonedUS20230287056A1 (en)2011-05-132023-04-27Pre-fusion rsv f antigens
US18/596,426AbandonedUS20240239845A1 (en)2011-05-132024-03-05Pre-fusion rsv f antigens
US18/895,059PendingUS20250042951A1 (en)2011-05-132024-09-24Pre-fusion rsv f antigens

Country Status (24)

CountryLink
US (8)US20140248314A1 (en)
EP (2)EP2707385B1 (en)
JP (1)JP2014519819A (en)
CN (1)CN103842374A (en)
AU (1)AU2012255971A1 (en)
BR (1)BR112013029169B1 (en)
CA (1)CA2835644C (en)
CY (2)CY1119849T1 (en)
DK (2)DK2707385T3 (en)
ES (2)ES2782119T3 (en)
FR (1)FR23C1046I2 (en)
HR (2)HRP20171703T1 (en)
HU (2)HUE048777T2 (en)
LT (2)LT3275892T (en)
MX (1)MX351011B (en)
NO (1)NO2707385T3 (en)
PL (2)PL2707385T3 (en)
PT (2)PT2707385T (en)
RS (1)RS56748B1 (en)
RU (1)RU2013155485A (en)
SG (1)SG194755A1 (en)
SI (2)SI3275892T1 (en)
SM (1)SMT201700569T1 (en)
WO (1)WO2012158613A1 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20140193484A1 (en)*2013-01-102014-07-10Sylvie Carine Bertholet GirardinInfluenza virus immunogenic compositions and uses thereof
US20140227346A1 (en)*2011-07-062014-08-14Andrew GeallImmunogenic combination compositions and uses thereof
US20140271699A1 (en)*2013-03-132014-09-18The United States Of America, As Represented By The Secretary, Department Of Health And Human ServPrefusion rsv f proteins and their use
US9095552B2 (en)2012-04-022015-08-04Moderna Therapeutics, Inc.Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9107886B2 (en)2012-04-022015-08-18Moderna Therapeutics, Inc.Modified polynucleotides encoding basic helix-loop-helix family member E41
US9181319B2 (en)2010-08-062015-11-10Moderna Therapeutics, Inc.Engineered nucleic acids and methods of use thereof
US9186372B2 (en)2011-12-162015-11-17Moderna Therapeutics, Inc.Split dose administration
US20160046675A1 (en)*2013-03-132016-02-18The USA, as represented by the Secretary, Departm- ent of Health and Human ServicePrefusion rsv f proteins and their use
US9283287B2 (en)2012-04-022016-03-15Moderna Therapeutics, Inc.Modified polynucleotides for the production of nuclear proteins
US9512456B2 (en)2012-08-142016-12-06Modernatx, Inc.Enzymes and polymerases for the synthesis of RNA
US9533047B2 (en)2011-03-312017-01-03Modernatx, Inc.Delivery and formulation of engineered nucleic acids
US9572897B2 (en)2012-04-022017-02-21Modernatx, Inc.Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9597380B2 (en)2012-11-262017-03-21Modernatx, Inc.Terminally modified RNA
WO2017040387A3 (en)*2015-08-312017-04-20Technovax, Inc.Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
US9701965B2 (en)2010-10-012017-07-11Modernatx, Inc.Engineered nucleic acids and methods of use thereof
US9950058B2 (en)2015-12-232018-04-24Pfizer Inc.RSV F protein mutants
US10023626B2 (en)2013-09-302018-07-17Modernatx, Inc.Polynucleotides encoding immune modulating polypeptides
US10258698B2 (en)2013-03-142019-04-16Modernatx, Inc.Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US10294279B2 (en)2013-06-172019-05-21Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F polypeptides
WO2019178521A1 (en)*2018-03-162019-09-19University Of Pittsburgh-Of The Commonwealth System Of Higher EducationCompositions and methods for vaccination against respiratory syncitial virus infection
CN110352072A (en)*2016-10-032019-10-18马萨诸塞大学 Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
US10457708B2 (en)2015-07-072019-10-29Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F polypeptides
US10456462B2 (en)2015-07-072019-10-29Janssen Vaccines & Preventions B.V.Vaccine against RSV
US10654898B2 (en)2015-01-202020-05-19The United States of America, as represented by the Secretary, Department of Health and Human SericesRecombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof
US10729757B2 (en)2016-04-052020-08-04Janssen Vaccines & Prevention B.V.Vaccine against RSV
US10849920B2 (en)2015-10-052020-12-01Modernatx, Inc.Methods for therapeutic administration of messenger ribonucleic acid drugs
US10899800B2 (en)2013-04-252021-01-26Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F polypeptides
US10953087B2 (en)2016-05-302021-03-23Janssen Vaccines & Prevention B.V.Stabilized pre-fusion RSV F proteins
US11155583B2 (en)2016-04-052021-10-26Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F proteins
US11192926B2 (en)2017-04-042021-12-07University Of WashingtonSelf-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
US11229695B2 (en)2017-09-152022-01-25Janssen Vaccines & Prevention B.V.Method for the safe induction of immunity against RSV
US11229692B2 (en)2017-05-172022-01-25Janssen Vaccines & Prevention B.V.Methods and compositions for inducing protective immunity against RSV infection
US20220125723A1 (en)2010-07-062022-04-28Glaxosmithkline Biologicals SaLipid formulations with viral immunogens
US11447566B2 (en)2018-01-042022-09-20Iconic Therapeutics, Inc.Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
US11464848B2 (en)2017-03-152022-10-11Modernatx, Inc.Respiratory syncytial virus vaccine
US11485759B2 (en)2014-11-032022-11-01University Of WashingtonPolypeptides for use in self-assembling protein nanostructures
US11497807B2 (en)*2017-03-172022-11-15Modernatx, Inc.Zoonotic disease RNA vaccines
US11504421B2 (en)2017-05-082022-11-22Gritstone Bio, Inc.Alphavirus neoantigen vectors
US11591619B2 (en)2019-05-302023-02-28Gritstone Bio, Inc.Modified adenoviruses
US11596645B2 (en)2010-07-062023-03-07Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11603399B2 (en)2013-03-132023-03-14Modernatx, Inc.Long-lived polynucleotide molecules
US11639370B2 (en)2010-10-112023-05-02Glaxosmithkline Biologicals SaAntigen delivery platforms
US11655475B2 (en)2010-07-062023-05-23Glaxosmithkline Biologicals SaImmunisation of large mammals with low doses of RNA
US11759422B2 (en)2010-08-312023-09-19Glaxosmithkline Biologicals SaPegylated liposomes for delivery of immunogen-encoding RNA
US11771755B2 (en)2018-02-282023-10-03University Of WashingtonSelf-asssembling nanostructure vaccines
US11771747B2 (en)2020-08-062023-10-03Gritstone Bio, Inc.Multiepitope vaccine cassettes
US20230310570A1 (en)*2020-08-172023-10-05University Of Pittsburgh-Of The Commonwealth System Of Higher EducationCompositions and methods for vaccination of juveniles againstrespiratory syncytial virus infection
US11911453B2 (en)2018-01-292024-02-27Modernatx, Inc.RSV RNA vaccines
CN117736278A (en)*2023-12-252024-03-22英诺特(唐山)生物技术有限公司Kit and detection method for detecting respiratory syncytial virus infection
CN118108812A (en)*2023-05-042024-05-31国药中生生物技术研究院有限公司 RSV F protein mutants
WO2025031486A1 (en)*2023-08-092025-02-13深圳瑞吉生物科技有限公司Respiratory syncytial virus antigenic polypeptide, vaccine, and use
US12331077B2 (en)2018-11-132025-06-17Janssen Vaccines & Prevention B.V.Stabilized pre-fusion RSV F proteins

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
PL3178490T3 (en)2009-07-152022-08-01Glaxosmithkline Biologicals S.A.Rsv f protein compositions and methods for making same
WO2012116715A1 (en)2011-03-022012-09-07Curevac GmbhVaccination in newborns and infants
LT3275892T (en)2011-05-132020-04-10Glaxosmithkline Biologicals S.A.Pre-fusion rsv f antigens
US9464124B2 (en)2011-09-122016-10-11Moderna Therapeutics, Inc.Engineered nucleic acids and methods of use thereof
KR102014061B1 (en)2011-10-032019-08-28모더나 세라퓨틱스, 인코포레이티드Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
PL2970981T3 (en)2013-03-142021-07-05Emory UniversityRecombinant rsv with silent mutations, vaccines, and methods related thereto
PL403149A1 (en)*2013-03-142014-09-15Celon Pharma Spółka AkcyjnaNew pirazolilobenzo[d]imidazole derivatives
US9060975B2 (en)*2013-03-142015-06-23Mucosis BvHeat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
US8980864B2 (en)2013-03-152015-03-17Moderna Therapeutics, Inc.Compositions and methods of altering cholesterol levels
EP3677279A1 (en)2013-07-252020-07-08Calder Biosciences Inc.Conformationally stabilized rsv pre-fusion f proteins
SG11201510746WA (en)2013-08-212016-03-30Curevac AgRespiratory syncytial virus (rsv) vaccine
CA2925201A1 (en)*2013-09-242015-04-02Massachusetts Institute Of TechnologySelf-assembled nanoparticle vaccines
BR112016007255A2 (en)2013-10-032017-09-12Moderna Therapeutics Inc polynucleotides encoding low density lipoprotein receptor
EP2974739A1 (en)*2014-07-152016-01-20Novartis AGRSVF trimerization domains
EP3888676A1 (en)2014-06-132021-10-06GlaxoSmithKline Biologicals S.A.Immunogenic combinations
TWI733653B (en)*2014-09-232021-07-21美商百靈佳殷格翰動物保健美國有限公司Fmdv recombinant vaccines and uses thereof
US10420834B2 (en)2014-12-242019-09-24The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesRecombinant metapneumovirus F proteins and their use
EP3344288A1 (en)*2015-09-022018-07-11Janssen Vaccines & Prevention B.V.Stabilized viral class i fusion proteins
MX2018005462A (en)2015-10-292018-08-01Univ EmoryChimeric RSV, Immunogenic Compositions, and Methods of Use.
CA3015570A1 (en)2016-03-292017-10-05Peter KwongSubstitutions-modified prefusion rsv f proteins and their use
WO2017207477A1 (en)2016-05-302017-12-07Janssen Vaccines & Prevention B.V.Stabilized pre-fusion rsv f proteins
CN106432438A (en)*2016-11-282017-02-22烟台偌帝生物工程有限公司Bovine respiratory syncytial virus antigen protein
CN106397547A (en)*2016-11-282017-02-15烟台偌帝生物工程有限公司Bovine respiration syncytial virus antigen protein
CN106432436A (en)*2016-11-282017-02-22烟台偌帝生物工程有限公司Antigen protein for bovine respiratory tract syncytial virus
CN106749556A (en)*2016-11-282017-05-31烟台偌帝生物工程有限公司A kind of bovine respiratory born of the same parents zoarium viral antigen proteins
CN106432435A (en)*2016-11-282017-02-22烟台偌帝生物工程有限公司Bovine respiration syncytial virus antigen protein
CN106432437A (en)*2016-11-282017-02-22烟台偌帝生物工程有限公司Antigen protein of bovine respiration syncytial viruses
CN106749555A (en)*2016-11-282017-05-31烟台偌帝生物工程有限公司A kind of bovine respiratory born of the same parents zoarium viral antigen proteins
CN106432439A (en)*2016-11-282017-02-22烟台偌帝生物工程有限公司Bovine respiratory syncytial virus antigen protein
CN106518988A (en)*2016-11-282017-03-22烟台偌帝生物工程有限公司Bovine respiratory syncytial cell virus antigen protein
GB201621686D0 (en)2016-12-202017-02-01Glaxosmithkline Biologicals SaNovel methods for inducing an immune response
CN108265079A (en)*2017-01-022018-07-10刘昕 Preparation method of a novel respiratory syncytial virus pre-F fusion protein vector
SG11201908280SA (en)*2017-03-302019-10-30Univ Queensland"chimeric molecules and uses thereof"
AU2018269319A1 (en)2017-05-152019-11-07Janssen Vaccines & Prevention B.V.Stable virus-containing composition
KR102658198B1 (en)2017-05-152024-04-16얀센 백신스 앤드 프리벤션 비.브이. Stable virus-containing composition
GB2577232B (en)2017-05-302022-07-06Glaxosmithkline Biologicals SaNovel methods for manufacturing an adjuvant
EP4295866A3 (en)*2017-06-142024-03-20Virometix AGCyclic peptides for protection against respiratory syncytial virus
CA3072293A1 (en)2017-08-072019-02-14Avatar Medical, LlcConformationally stabilized rsv pre-fusion f proteins
CN111670044A (en)2017-12-012020-09-15葛兰素史密丝克莱恩生物有限公司 Saponin purification
CN112292395A (en)2018-04-172021-01-29库瑞瓦格股份公司 Novel RSV RNA molecules and compositions for vaccination
BR112021000965A2 (en)2018-08-072021-04-27Glaxosmithkline Biologicals S.A. processes and vaccines
WO2020124846A1 (en)*2018-12-182020-06-25珠海泰诺麦博生物技术有限公司Neutralizing antibody against respiratory syncytial virus and use thereof
CN109851678A (en)*2019-03-072019-06-07苏州宇之波生物科技有限公司A kind of inferior stable state bovine respiratory syncytial virus of improvement merges DNA molecular and its application of precursor F protein matter and coding
JP7640473B2 (en)2019-06-052025-03-05グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Saponin Purification
WO2021046207A1 (en)2019-09-042021-03-11University Of WashingtonSelf-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP4142785A2 (en)*2020-04-292023-03-08The United States of America, as represented by the Secretary, Department of Health and Human ServicesRecombinant human metapneumovirus f proteins and their use
WO2021253172A1 (en)*2020-06-152021-12-23上海市公共卫生临床中心Method for inducing anti-novel coronavirus neutralizing antibody using receptor recognition domain
CN113801206B (en)*2020-06-152024-07-02上海市公共卫生临床中心 Method for inducing anti-new coronavirus neutralizing antibodies using receptor recognition domain
CN114213548B (en)*2020-12-242024-10-29上海市公共卫生临床中心Method for simultaneously inducing immune responses against multiple viruses
EP4294436A1 (en)2021-02-192023-12-27Janssen Vaccines & Prevention B.V.Stabilized pre-fusion rsv fb fantigens
US20240415949A1 (en)*2021-10-182024-12-19Jiangsu Recbio Technology Co., Ltd.Mucosal vaccine, methods of use and administration thereof
EP4169513A1 (en)2021-10-192023-04-26GlaxoSmithKline Biologicals S.A.Adjuvant composition comprising sting agonists
KR20250113423A (en)*2022-11-092025-07-25세퀴러스 인코포레이티드 Stabilized vaccine
CN120569211A (en)*2023-01-092025-08-29得克萨斯州大学系统董事会Human parainfluenza virus 3F protein stabilized before fusion
WO2024175040A1 (en)*2023-02-222024-08-29Everest Medicines (China) Co., Ltd.RSV mRNA VACCINES
CN119569835A (en)*2023-09-072025-03-07北京科兴中维生物技术有限公司 Respiratory syncytial virus F protein and its application
EP4520334A1 (en)2023-09-072025-03-12Mnemo TherapeuticsMethods and compositions for improving immune response
WO2025052001A1 (en)2023-09-072025-03-13Mnemo TherapeuticsMethods and compositions for improving immune response
WO2025097030A1 (en)*2023-11-022025-05-08Oregon State UniversityVirus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
CN117586359A (en)*2024-01-192024-02-23北京安百胜生物科技有限公司Respiratory Syncytial Virus (RSV) polypeptides having immunogenicity

Citations (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2010149743A2 (en)*2009-06-242010-12-29Id Biomedical Corporation Of QuebecVaccine

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US120A (en)1837-02-10Mode of constructing steelyard-balances
US4186745A (en)1976-07-301980-02-05Kauzlarich James JPorous catheters
US4235877A (en)1979-06-271980-11-25Merck & Co., Inc.Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en)1979-11-131983-02-08Likhite Vilas VAntigen compounds
IL61904A (en)1981-01-131985-07-31Yeda Res & DevSynthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en)1982-05-261989-09-12Ribi Immunochem Research Inc.Refined detoxified endotoxin
US4436727A (en)1982-05-261984-03-13Ribi Immunochem Research, Inc.Refined detoxified endotoxin product
SE8205892D0 (en)1982-10-181982-10-18Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
EP0114787B1 (en)1983-01-251991-09-25Ciba-Geigy AgPeptide derivatives
IL73534A (en)1983-11-181990-12-23Riker Laboratories Inc1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en)1984-04-122000-07-18The Liposome Company, Inc.Potentiation of immune responses with liposomal adjuvants
US5916588A (en)1984-04-121999-06-29The Liposome Company, Inc.Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4797368A (en)1985-03-151989-01-10The United States Of America As Represented By The Department Of Health And Human ServicesAdeno-associated virus as eukaryotic expression vector
US4707543A (en)1985-09-171987-11-17The United States Of America As Represented By The Secretary Of The ArmyProcess for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4680338A (en)1985-10-171987-07-14Immunomedics, Inc.Bifunctional linker
US5011828A (en)1985-11-151991-04-30Michael GoodmanImmunostimulating guanine derivatives, compositions and methods
US5149650A (en)1986-01-141992-09-22University Of North Carolina At Chapel HillVaccines for human respiratory virus
US4877611A (en)1986-04-151989-10-31Ribi Immunochem Research Inc.Vaccine containing tumor antigens and adjuvants
US5057540A (en)1987-05-291991-10-15Cambridge Biotech CorporationSaponin adjuvant
CA1331443C (en)1987-05-291994-08-16Charlotte A. KensilSaponin adjuvant
US5726292A (en)1987-06-231998-03-10Lowell; George H.Immuno-potentiating systems for preparation of immunogenic materials
US5639853A (en)1987-09-291997-06-17Praxis Biologics, Inc.Respiratory syncytial virus vaccines
US5194595A (en)1987-12-231993-03-16The Upjohn CompanyChimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
JPH0731857B2 (en)1988-02-191995-04-10三洋電機株式会社 Reel base drive device in magnetic recording / reproducing apparatus
US5278302A (en)1988-05-261994-01-11University Patents, Inc.Polynucleotide phosphorodithioates
US4912094B1 (en)1988-06-291994-02-15Ribi Immunochem Research Inc.Modified lipopolysaccharides and process of preparation
NZ230423A (en)1988-08-251993-08-26Liposome Co IncA dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
US5238944A (en)1988-12-151993-08-24Riker Laboratories, Inc.Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en)1989-03-231990-05-29Minnesota Mining And Manufacturing CompanyOlefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en)1989-05-251996-11-12Gary Van NestAdjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en)1989-10-261991-01-29Riker Laboratories, Inc.3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
JP3056782B2 (en)1989-11-032000-06-26ヴァンダービルト ユニバーシティ Pharmaceutical compositions for expression of genes in target organs
US5674192A (en)1990-12-281997-10-07Boston Scientific CorporationDrug delivery
US5279833A (en)1990-04-041994-01-18Yale UniversityLiposomal transfection of nucleic acids into animal cells
US5658731A (en)1990-04-091997-08-19Europaisches Laboratorium Fur Molekularbiologie2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5173414A (en)1990-10-301992-12-22Applied Immune Sciences, Inc.Production of recombinant adeno-associated virus vectors
SG70625A1 (en)1991-03-012000-02-22Minnesota Mining & Mfg1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines
US5389640A (en)1991-03-011995-02-14Minnesota Mining And Manufacturing Company1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5936076A (en)1991-08-291999-08-10Kirin Beer Kabushiki Kaishaαgalactosylceramide derivatives
US5268376A (en)1991-09-041993-12-07Minnesota Mining And Manufacturing Company1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en)1991-11-061993-11-30Minnesota Mining And Manufacturing Company2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MY111880A (en)1992-03-272001-02-28Smithkline Beecham Biologicals S AHepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
IL105325A (en)1992-04-161996-11-14Minnesota Mining & MfgImmunogen/vaccine adjuvant composition
US5340740A (en)1992-05-151994-08-23North Carolina State UniversityMethod of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5587308A (en)1992-06-021996-12-24The United States Of America As Represented By The Department Of Health & Human ServicesModified adeno-associated virus vector capable of expression from a novel promoter
WO1993025673A1 (en)1992-06-041993-12-23The Regents Of The University Of CaliforniaIn vivo gene therapy with intron-free sequence of interest
SG90042A1 (en)1992-06-252002-07-23Smithkline Beecham BiologVaccine composition containing adjuvants
WO1994015968A1 (en)1993-01-081994-07-21The Upjohn CompanyProcess for the purification and refolding of human respiratory syncytial virus fg glycoprotein
US5395937A (en)1993-01-291995-03-07Minnesota Mining And Manufacturing CompanyProcess for preparing quinoline amines
BR9405957A (en)1993-03-231995-12-12Smithkline Beecham Biolog Vaccine compositions containing 3-0 monophosphoryl deacylated lipid A
DK0708772T3 (en)1993-07-152000-09-18Minnesota Mining & Mfg Imidazo [4,5-c] pyridin-4-amines
US5352784A (en)1993-07-151994-10-04Minnesota Mining And Manufacturing CompanyFused cycloalkylimidazopyridines
AU5543294A (en)1993-10-291995-05-22Pharmos Corp.Submicron emulsions as vaccine adjuvants
US5961970A (en)1993-10-291999-10-05Pharmos CorporationSubmicron emulsions as vaccine adjuvants
EP0729473B1 (en)1993-11-172000-08-23OM PharmaGlucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
US5397307A (en)1993-12-071995-03-14Schneider (Usa) Inc.Drug delivery PTCA catheter and method for drug delivery
GB9326174D0 (en)1993-12-221994-02-23Biocine SclavoMucosal adjuvant
GB9326253D0 (en)1993-12-231994-02-23Smithkline Beecham BiologVaccines
JP3403233B2 (en)1994-01-202003-05-06テルモ株式会社 Balloon catheter
WO1995026204A1 (en)1994-03-251995-10-05Isis Pharmaceuticals, Inc.Immune stimulation by phosphorothioate oligonucleotide analogs
FR2718452B1 (en)1994-04-061996-06-28Pf Medicament Element of immunogen, immunogenic agent, pharmaceutical composition and method of preparation.
CA2560114A1 (en)1994-07-151996-02-01The University Of Iowa Research FoundationImmunomodulatory oligonucleotides
US6207646B1 (en)1994-07-152001-03-27University Of Iowa Research FoundationImmunostimulatory nucleic acid molecules
US6429199B1 (en)1994-07-152002-08-06University Of Iowa Research FoundationImmunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en)1994-07-152001-05-29University Of Iowa Research FoundationImmunostimulatory nucleic acid molecules
AUPM873294A0 (en)1994-10-121994-11-03Csl LimitedSaponin preparations and use thereof in iscoms
FR2726003B1 (en)1994-10-212002-10-18Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
DE69536153D1 (en)1994-11-172011-05-05Ich Productions Ltd INTERNALIZATION OF DNA, USING CONJUGATES OF POLY-L-LYSINE AND A PEPTIDE LIGAND OF THE INTEGRIN RECEPTOR
US6071890A (en)1994-12-092000-06-06Genzyme CorporationOrgan-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5482936A (en)1995-01-121996-01-09Minnesota Mining And Manufacturing CompanyImidazo[4,5-C]quinoline amines
GB9503863D0 (en)1995-02-251995-04-19Smithkline Beecham BiologVaccine compositions
UA56132C2 (en)1995-04-252003-05-15Смітклайн Бічем Байолоджікалс С.А.Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5811524A (en)1995-06-071998-09-22Idec Pharmaceuticals CorporationNeutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5666153A (en)1995-10-031997-09-09Virtual Shopping, Inc.Retractable teleconferencing apparatus
US5856462A (en)1996-09-101999-01-05Hybridon IncorporatedOligonucleotides having modified CpG dinucleosides
EP1005368B1 (en)1997-03-102009-09-02Ottawa Hospital Research InstituteUse of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6818222B1 (en)1997-03-212004-11-16Chiron CorporationDetoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6303347B1 (en)1997-05-082001-10-16Corixa CorporationAminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en)1997-05-082004-07-20Corixa CorporationAminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en)1997-05-082000-09-05Ribi Immunochem Research, Inc.Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en)1997-05-202000-06-27Galenica Pharmaceuticals, Inc.Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6060308A (en)1997-09-042000-05-09Connaught Laboratories LimitedRNA respiratory syncytial virus vaccines
US6090619A (en)1997-09-082000-07-18University Of FloridaMaterials and methods for intracellular delivery of biologically active molecules
DE69828801T2 (en)1997-09-192005-07-14Wyeth Holdings Corp. PEPTIDE, DERIVED FROM THE FEDERATED G-PROTEIN OF THE RESPIRATORY SYNCYTIAL VIRUS
EP0980280B1 (en)1997-10-012005-02-09Medtronic Ave, Inc.Drug delivery and gene therapy delivery system
GB9725084D0 (en)1997-11-281998-01-28Medeva Europ LtdVaccine compositions
GB9727262D0 (en)1997-12-241998-02-25Smithkline Beecham BiologVaccine
JP2002511423A (en)1998-04-092002-04-16スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
US6562798B1 (en)1998-06-052003-05-13Dynavax Technologies Corp.Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO1999064301A1 (en)1998-06-081999-12-16Sca Emballage FranceFast flattening packaging
WO2000000462A1 (en)1998-06-302000-01-06Om PharmaNovel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
US6110929A (en)1998-07-282000-08-293M Innovative Properties CompanyOxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en)1998-08-051998-09-30Smithkline Beecham BiologVaccine
EP1126876B1 (en)1998-10-162007-03-21GlaxoSmithKline Biologicals S.A.Adjuvant systems and vaccines
US20030130212A1 (en)1999-01-142003-07-10Rossignol Daniel P.Administration of an anti-endotoxin drug by intravenous infusion
US20040006242A1 (en)1999-02-012004-01-08Hawkins Lynn D.Immunomodulatory compounds and method of use thereof
US6551600B2 (en)1999-02-012003-04-22Eisai Co., Ltd.Immunological adjuvant compounds compositions and methods of use thereof
ES2228467T3 (en)1999-02-032005-04-16Biosante Pharmaceuticals, Inc. THERAPEUTIC PARTICLES OF CALCIUM PHOSPHATE AND METHODS OF MANUFACTURE AND ITS USE.
ES2308069T3 (en)1999-03-262008-12-01Vical Incorporated ADJUSTMENT COMPOSITIONS TO IMMUNE IMMUNORESPUESTAS TO POLINUCLEOTIDO-BASED VACCINES.
US6331539B1 (en)1999-06-102001-12-183M Innovative Properties CompanySulfonamide and sulfamide substituted imidazoquinolines
BR0014282A (en)1999-09-242002-05-21Smithkline Beecham Biolog Vaccines
CN1399539A (en)1999-09-242003-02-26史密丝克莱恩比彻姆生物有限公司Adjuvant comprising polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HUP0202639A2 (en)1999-09-252002-12-28Coley Pharm GmbhImmunostimulatory nucleic acids
AU1581400A (en)1999-12-222001-07-03Om PharmaAcyl pseudopeptides bearing a functionalised auxiliary spacer
AU3108001A (en)2000-01-202001-12-24Coley Pharmaceutical Group, Inc.Immunostimulatory nucleic acids for inducing a th2 immune response
AU2001293233A1 (en)2000-09-012002-03-13Chiron CorporationAza heterocyclic derivatives and their therapeutic use
ES2250480T3 (en)2000-09-112006-04-16Chiron Corporation DERIVATIVES OF QUINOLINONE AS INHIBITORS OF TYROSINE QUINASA.
AU9475001A (en)2000-09-262002-04-08Hybridon IncModulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US20040161846A1 (en)2000-11-222004-08-19Mason Anthony JohnMethod of expression and agents identified thereby
US6667312B2 (en)2000-12-082003-12-233M Innovative Properties CompanyThioether substituted imidazoquinolines
US6664264B2 (en)2000-12-082003-12-163M Innovative Properties CompanyThioether substituted imidazoquinolines
US6677348B2 (en)2000-12-082004-01-133M Innovative Properties CompanyAryl ether substituted imidazoquinolines
UA75622C2 (en)2000-12-082006-05-153M Innovative Properties CoAryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6677347B2 (en)2000-12-082004-01-133M Innovative Properties CompanySulfonamido ether substituted imidazoquinolines
US6664265B2 (en)2000-12-082003-12-163M Innovative Properties CompanyAmido ether substituted imidazoquinolines
EP1395669B1 (en)2001-01-262009-07-22Selexis S.A.Matrix attachment regions and methods for use thereof
JP4137640B2 (en)2001-03-092008-08-20アイディー バイオメディカル コーポレイション オブ ケベック Novel proteosome-liposaccharide vaccine adjuvant
ATE404561T1 (en)2001-04-172008-08-15Dainippon Sumitomo Pharma Co NEW ADENINE DERIVATIVES
WO2003035836A2 (en)2001-10-242003-05-01Hybridon Inc.Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2003043572A2 (en)2001-11-162003-05-303M Innovative Properties CompanyMethods and compositions related to irm compounds and toll-like receptor pathways
FR2832423B1 (en)2001-11-222004-10-08Vivalis EXOGENOUS PROTEIN EXPRESSION SYSTEM IN AN AVIAN SYSTEM
EA008380B1 (en)2001-11-272007-04-27Анадис Фармасьютикалз, Инк.3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIMIDINE NUCLEOSIDES AND USES THEREOF
US7321033B2 (en)2001-11-272008-01-22Anadys Pharmaceuticals, Inc.3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en)2001-12-212004-01-133M Innovative Properties CompanySulfonamide and sulfamide substituted imidazoquinolines
JP4553588B2 (en)2002-02-212010-09-29メディミューン,エルエルシー Metapneumovirus strains and their use in vaccine formulations and as vectors for antigen sequence expression
FR2836924B1 (en)2002-03-082005-01-14Vivalis AVIAN CELL LINES USEFUL FOR THE PRODUCTION OF INTEREST SUBSTANCES
ES2336094T3 (en)2002-03-292010-04-08Novartis Vaccines And Diagnostics, Inc. BENZAZOLES REPLACED AND USE OF THE SAME AS INHIBITORS OF QUINASA RAF.
AU2003227049A1 (en)2002-04-032003-10-13Akzo Nobel N.V.Viral mutants, manipulated in the furin cleavage sites of glycoproteins
AU2003233519A1 (en)2002-05-292003-12-193M Innovative Properties CompanyProcess for imidazo(4,5-c)pyridin-4-amines
EP1551228B1 (en)2002-06-132012-10-03New York UniversitySynthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
JP2006501243A (en)2002-08-232006-01-12カイロン コーポレイション A pyrrole-based inhibitor of glycogen synthase kinase 3
AU2003301148A1 (en)2002-12-232004-07-22Vical IncorporatedCodon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
WO2004060308A2 (en)2002-12-272004-07-22Chiron CorporationThiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en)2003-01-212012-06-05Novartis Vaccines And Diagnostics, Inc.Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en)2003-01-232003-02-26Molecularnature LtdImmunostimulatory compositions
EP1592302A4 (en)2003-02-132007-04-253M Innovative Properties CoMethods and compositions related to irm compounds and toll-like receptor 8
EP1608369B1 (en)2003-03-282013-06-26Novartis Vaccines and Diagnostics, Inc.Use of organic compounds for immunopotentiation
US7368537B2 (en)2003-07-152008-05-06Id Biomedical Corporation Of QuebecSubunit vaccine against respiratory syncytial virus infection
RU2236257C1 (en)2003-09-152004-09-20Косяков Константин СергеевичSynthetic immunogen for therapy and prophylaxis of addiction with narcotic and psychoactive substances
US7771726B2 (en)2003-10-082010-08-10New York UniversityUse of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US8252917B2 (en)2003-10-242012-08-28Selexis S.A.High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of MAR sequences
EP1528101A1 (en)2003-11-032005-05-04ProBioGen AGImmortalized avian cell lines for virus production
AU2005235080A1 (en)2004-03-312005-11-03New York UniversityNovel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
KR20070008625A (en)2004-04-052007-01-17화이자 프로덕츠 인코포레이티드 Microfluidized Oil-in-water Emulsions and Vaccine Compositions
CA2566355C (en)2004-05-182014-04-15Vical IncorporatedInfluenza virus vaccine composition and methods of use
EP2277595A3 (en)2004-06-242011-09-28Novartis Vaccines and Diagnostics, Inc.Compounds for immunopotentiation
FR2873378A1 (en)2004-07-232006-01-27Pierre Fabre Medicament Sa IMMUNOGENIC COMPLEXES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
ES2355980T3 (en)2004-07-232011-04-01Novartis Vaccines And Diagnostics S.R.L. POLYPEPTIDES FOR OLIGOMERIC ANTIGEN ASSEMBLY.
GB0422439D0 (en)2004-10-082004-11-10European Molecular Biology Lab EmblInhibitors of infection
US8846051B2 (en)2004-10-082014-09-30The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And PreventionModulation of replicative fitness by deoptimization of synonymous codons
TWI457133B (en)2005-12-132014-10-21Glaxosmithkline Biolog SaNovel composition
EP2089515A4 (en)2006-11-162011-02-23Novavax IncRespiratory syncytial virus-virus like particle (vlps)
WO2008114149A2 (en)2007-03-212008-09-25Id Biomedical Corporation Of QuebecChimeric antigens
EP2164860A2 (en)2007-06-062010-03-24Nationwide Children's Hospital, Inc.Methods and compositions relating to viral fusion proteins
RS55162B1 (en)*2007-12-242017-01-31Id Biomedical Corp Quebec RECOMBINANT RSV ANTIGENS
CN102015651B (en)2008-03-032014-12-31Irm责任有限公司Compounds and compositions as TLR activity modulators
JP2011519828A (en)2008-04-182011-07-14バクシネート コーポレーション Flagellin deletion mutants and methods of use
WO2009132206A1 (en)2008-04-252009-10-29Liquidia Technologies, Inc.Compositions and methods for intracellular delivery and release of cargo
US20110250237A1 (en)2008-07-152011-10-13O'hagan DerekImmunogenic amphipathic peptide compositions
MX2011000668A (en)2008-07-182011-07-29Id Biomedical Corp QuebecChimeric respiratory syncytial virus polypeptide antigens.
HUE029037T2 (en)2008-12-092017-01-30Novavax Inc Modified RSV F proteins and methods of application
WO2010077712A1 (en)2008-12-092010-07-08Novavax, Inc.Bovine respiratory syncytial virus virus-like particle (vlps)
WO2010149745A1 (en)*2009-06-242010-12-29Glaxosmithkline Biologicals S.A.Recombinant rsv antigens
PL3178490T3 (en)2009-07-152022-08-01Glaxosmithkline Biologicals S.A.Rsv f protein compositions and methods for making same
US9405700B2 (en)2010-11-042016-08-02Sonics, Inc.Methods and apparatus for virtualization in an integrated circuit
WO2012128628A1 (en)2011-03-222012-09-27Mucosis B.V.Immunogenic compositions in particulate form and methods for producing the same
LT3275892T (en)2011-05-132020-04-10Glaxosmithkline Biologicals S.A.Pre-fusion rsv f antigens
ES2395677B1 (en)2011-07-292013-12-26Instituto De Salud Carlos Iii VRSH F protein in stabilized pre-fusion conformation and specific neutralizing antibodies against it.
US9738689B2 (en)*2013-03-132017-08-22The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPrefusion RSV F proteins and their use
EP3207146B1 (en)2014-10-152021-09-29Amgen Inc.Promoter and regulatory elements for improved expression of heterologous genes in host cells
SG11201908280SA (en)2017-03-302019-10-30Univ Queensland"chimeric molecules and uses thereof"

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2010149743A2 (en)*2009-06-242010-12-29Id Biomedical Corporation Of QuebecVaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ruiz- Arguello et al. (J General Virology 2004, Vol 85, pages 3677-3687*

Cited By (134)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US11690863B2 (en)2010-07-062023-07-04Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11690862B1 (en)2010-07-062023-07-04Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US12186333B2 (en)2010-07-062025-01-07Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11913001B2 (en)2010-07-062024-02-27Glaxosmithkline Biologicals SaImmunisation of large mammals with low doses of RNA
US11905514B2 (en)2010-07-062024-02-20Glaxosmithkline Biological SaImmunisation of large mammals with low doses of RNA
US11596645B2 (en)2010-07-062023-03-07Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11891608B2 (en)2010-07-062024-02-06Glaxosmithkline Biologicals SaImmunization of large mammals with low doses of RNA
US11638693B2 (en)2010-07-062023-05-02Glaxosmithkline Biologicals SaVaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids
US11638694B2 (en)2010-07-062023-05-02Glaxosmithkline Biologicals SaVaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens
US11883534B2 (en)2010-07-062024-01-30Glaxosmithkline Biologicals SaImmunisation with lipid formulations with RNA encoding immunogens
US11865080B2 (en)2010-07-062024-01-09Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11857562B2 (en)2010-07-062024-01-02Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11857681B2 (en)2010-07-062024-01-02Glaxosmithkline Biologicals SaLipid formulations with RNA encoding immunogens
US11851660B2 (en)2010-07-062023-12-26Glaxosmithkline Biologicals SaImmunisation of large mammals with low doses of RNA
US11850305B2 (en)2010-07-062023-12-26Glaxosmithkline Biologicals SaMethod of making lipid formulations with RNA encoding immunogens
US11845925B2 (en)2010-07-062023-12-19Glaxosmithkline Biologicals SaImmunisation of large mammals with low doses of RNA
US11839686B2 (en)2010-07-062023-12-12Glaxosmithkline Biologicals SaLipid formulations with viral immunogens
US11786467B2 (en)2010-07-062023-10-17Glaxosmithkline Biologicals SaLipid formulations with immunogens
US11773395B1 (en)2010-07-062023-10-03Glaxosmithkline Biologicals SaImmunization of large mammals with low doses of RNA
US11655475B2 (en)2010-07-062023-05-23Glaxosmithkline Biologicals SaImmunisation of large mammals with low doses of RNA
US11666534B2 (en)2010-07-062023-06-06Glaxosmithkline Biologicals SaMethods of administering lipid formulations with viral immunogens
US11690864B2 (en)2010-07-062023-07-04Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11690861B2 (en)2010-07-062023-07-04Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11759475B2 (en)2010-07-062023-09-19Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US20220125723A1 (en)2010-07-062022-04-28Glaxosmithkline Biologicals SaLipid formulations with viral immunogens
US11739334B2 (en)2010-07-062023-08-29Glaxosmithkline Biologicals SaImmunisation of large mammals with low doses of RNA
US11730754B2 (en)2010-07-062023-08-22Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11717529B2 (en)2010-07-062023-08-08Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11707482B2 (en)2010-07-062023-07-25Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11696923B2 (en)2010-07-062023-07-11Glaxosmithkline Biologicals, SaDelivery of RNA to trigger multiple immune pathways
US11690865B2 (en)2010-07-062023-07-04Glaxosmithkline Biologicals SaDelivery of RNA to trigger multiple immune pathways
US11766401B2 (en)2010-07-062023-09-26Glaxosmithkline Biologicals SaMethods of administering lipid formulations with immunogens
US9447164B2 (en)2010-08-062016-09-20Moderna Therapeutics, Inc.Engineered nucleic acids and methods of use thereof
US9937233B2 (en)2010-08-062018-04-10Modernatx, Inc.Engineered nucleic acids and methods of use thereof
US9181319B2 (en)2010-08-062015-11-10Moderna Therapeutics, Inc.Engineered nucleic acids and methods of use thereof
US11759422B2 (en)2010-08-312023-09-19Glaxosmithkline Biologicals SaPegylated liposomes for delivery of immunogen-encoding RNA
US9701965B2 (en)2010-10-012017-07-11Modernatx, Inc.Engineered nucleic acids and methods of use thereof
US11639370B2 (en)2010-10-112023-05-02Glaxosmithkline Biologicals SaAntigen delivery platforms
US9533047B2 (en)2011-03-312017-01-03Modernatx, Inc.Delivery and formulation of engineered nucleic acids
US9950068B2 (en)2011-03-312018-04-24Modernatx, Inc.Delivery and formulation of engineered nucleic acids
US20140227346A1 (en)*2011-07-062014-08-14Andrew GeallImmunogenic combination compositions and uses thereof
US11896636B2 (en)*2011-07-062024-02-13Glaxosmithkline Biologicals SaImmunogenic combination compositions and uses thereof
US9295689B2 (en)2011-12-162016-03-29Moderna Therapeutics, Inc.Formulation and delivery of PLGA microspheres
US9186372B2 (en)2011-12-162015-11-17Moderna Therapeutics, Inc.Split dose administration
US9814760B2 (en)2012-04-022017-11-14Modernatx, Inc.Modified polynucleotides for the production of biologics and proteins associated with human disease
US9255129B2 (en)2012-04-022016-02-09Moderna Therapeutics, Inc.Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9095552B2 (en)2012-04-022015-08-04Moderna Therapeutics, Inc.Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1
US9107886B2 (en)2012-04-022015-08-18Moderna Therapeutics, Inc.Modified polynucleotides encoding basic helix-loop-helix family member E41
US9114113B2 (en)2012-04-022015-08-25Moderna Therapeutics, Inc.Modified polynucleotides encoding citeD4
US9149506B2 (en)2012-04-022015-10-06Moderna Therapeutics, Inc.Modified polynucleotides encoding septin-4
US9192651B2 (en)2012-04-022015-11-24Moderna Therapeutics, Inc.Modified polynucleotides for the production of secreted proteins
US9216205B2 (en)2012-04-022015-12-22Moderna Therapeutics, Inc.Modified polynucleotides encoding granulysin
US9220792B2 (en)2012-04-022015-12-29Moderna Therapeutics, Inc.Modified polynucleotides encoding aquaporin-5
US9220755B2 (en)2012-04-022015-12-29Moderna Therapeutics, Inc.Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9221891B2 (en)2012-04-022015-12-29Moderna Therapeutics, Inc.In vivo production of proteins
US9233141B2 (en)2012-04-022016-01-12Moderna Therapeutics, Inc.Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
US9254311B2 (en)2012-04-022016-02-09Moderna Therapeutics, Inc.Modified polynucleotides for the production of proteins
US9878056B2 (en)2012-04-022018-01-30Modernatx, Inc.Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en)2012-04-022016-03-15Moderna Therapeutics, Inc.Modified polynucleotides for the production of nuclear proteins
US9301993B2 (en)2012-04-022016-04-05Moderna Therapeutics, Inc.Modified polynucleotides encoding apoptosis inducing factor 1
US9303079B2 (en)2012-04-022016-04-05Moderna Therapeutics, Inc.Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9828416B2 (en)2012-04-022017-11-28Modernatx, Inc.Modified polynucleotides for the production of secreted proteins
US9572897B2 (en)2012-04-022017-02-21Modernatx, Inc.Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9587003B2 (en)2012-04-022017-03-07Modernatx, Inc.Modified polynucleotides for the production of oncology-related proteins and peptides
US9827332B2 (en)2012-04-022017-11-28Modernatx, Inc.Modified polynucleotides for the production of proteins
US9675668B2 (en)2012-04-022017-06-13Moderna Therapeutics, Inc.Modified polynucleotides encoding hepatitis A virus cellular receptor 2
US9782462B2 (en)2012-04-022017-10-10Modernatx, Inc.Modified polynucleotides for the production of proteins associated with human disease
US9512456B2 (en)2012-08-142016-12-06Modernatx, Inc.Enzymes and polymerases for the synthesis of RNA
US9597380B2 (en)2012-11-262017-03-21Modernatx, Inc.Terminally modified RNA
US20140193484A1 (en)*2013-01-102014-07-10Sylvie Carine Bertholet GirardinInfluenza virus immunogenic compositions and uses thereof
US11130785B2 (en)2013-03-132021-09-28The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPrefusion RSV F proteins and their use
US9738689B2 (en)*2013-03-132017-08-22The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPrefusion RSV F proteins and their use
US11981707B2 (en)2013-03-132024-05-14The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPrefusion RSV F proteins and their use
US11603399B2 (en)2013-03-132023-03-14Modernatx, Inc.Long-lived polynucleotide molecules
US20140271699A1 (en)*2013-03-132014-09-18The United States Of America, As Represented By The Secretary, Department Of Health And Human ServPrefusion rsv f proteins and their use
US10858400B2 (en)2013-03-132020-12-08The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPrefusion RSV F proteins and their use
US10017543B2 (en)*2013-03-132018-07-10The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesPrefusion RSV F proteins and their use
US20160046675A1 (en)*2013-03-132016-02-18The USA, as represented by the Secretary, Departm- ent of Health and Human ServicePrefusion rsv f proteins and their use
US10258698B2 (en)2013-03-142019-04-16Modernatx, Inc.Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US10899800B2 (en)2013-04-252021-01-26Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F polypeptides
US10294279B2 (en)2013-06-172019-05-21Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F polypeptides
US10023626B2 (en)2013-09-302018-07-17Modernatx, Inc.Polynucleotides encoding immune modulating polypeptides
US10815291B2 (en)2013-09-302020-10-27Modernatx, Inc.Polynucleotides encoding immune modulating polypeptides
US11485759B2 (en)2014-11-032022-11-01University Of WashingtonPolypeptides for use in self-assembling protein nanostructures
US11591372B2 (en)2015-01-202023-02-28The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesRecombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof
US10654898B2 (en)2015-01-202020-05-19The United States of America, as represented by the Secretary, Department of Health and Human SericesRecombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof
US12018051B2 (en)2015-01-202024-06-25The U.S.A., As Represented By The Secretary, Department Of Health And Human ServicesRecombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof
US11034731B2 (en)2015-07-072021-06-15Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F polypeptides
US11229694B2 (en)2015-07-072022-01-25Janssen Vaccines & Prevention B.V.Vaccine against RSV
US10456462B2 (en)2015-07-072019-10-29Janssen Vaccines & Preventions B.V.Vaccine against RSV
US10457708B2 (en)2015-07-072019-10-29Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F polypeptides
US11998597B2 (en)2015-07-072024-06-04Janssen Vaccines & Prevention B.V.Vaccine against RSV
EP3344290A4 (en)*2015-08-312019-02-27Technovax, Inc. VIRAL PSEUDOPARTICLE (VLP) VACCINE AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV)
US11324816B2 (en)2015-08-312022-05-10Technovax, Inc.Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
WO2017040387A3 (en)*2015-08-312017-04-20Technovax, Inc.Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
US12246030B2 (en)2015-10-052025-03-11Modernatx, Inc.Methods for therapeutic administration of messenger ribonucleic acid drugs
US10849920B2 (en)2015-10-052020-12-01Modernatx, Inc.Methods for therapeutic administration of messenger ribonucleic acid drugs
US11590157B2 (en)2015-10-052023-02-28Modernatx, Inc.Methods for therapeutic administration of messenger ribonucleic acid drugs
US9950058B2 (en)2015-12-232018-04-24Pfizer Inc.RSV F protein mutants
US10821171B2 (en)2015-12-232020-11-03Pfizer Inc.RSV F protein mutants
US10238732B2 (en)2015-12-232019-03-26Pfizer Inc.RSV F protein mutants
US11801297B2 (en)2016-04-052023-10-31Janssen Vaccines & Prevention B.V.Vaccine against RSV
US12234264B2 (en)2016-04-052025-02-25Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F proteins
US10729757B2 (en)2016-04-052020-08-04Janssen Vaccines & Prevention B.V.Vaccine against RSV
US11338031B2 (en)2016-04-052022-05-24Janssen Vaccines & Prevention B.V.Vaccine against RSV
US11155583B2 (en)2016-04-052021-10-26Janssen Vaccines & Prevention B.V.Stabilized soluble pre-fusion RSV F proteins
US11759514B2 (en)2016-05-302023-09-19Janssen Vaccines & Prevention B.V.Stabilized pre-fusion RSV F proteins
US10953087B2 (en)2016-05-302021-03-23Janssen Vaccines & Prevention B.V.Stabilized pre-fusion RSV F proteins
CN110352072A (en)*2016-10-032019-10-18马萨诸塞大学 Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)
US11464848B2 (en)2017-03-152022-10-11Modernatx, Inc.Respiratory syncytial virus vaccine
US11497807B2 (en)*2017-03-172022-11-15Modernatx, Inc.Zoonotic disease RNA vaccines
US11192926B2 (en)2017-04-042021-12-07University Of WashingtonSelf-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
US11732011B2 (en)2017-04-042023-08-22University Of WashingtonSelf-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
US12275757B2 (en)2017-04-042025-04-15University Of WashingtonSelf-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use
US12109257B2 (en)2017-05-082024-10-08Gritstone Bio, Inc.Alphavirus neoantigen vectors
US11504421B2 (en)2017-05-082022-11-22Gritstone Bio, Inc.Alphavirus neoantigen vectors
US11510973B2 (en)2017-05-082022-11-29Gritstone Bio, Inc.Alphavirus antigen vectors
US11229692B2 (en)2017-05-172022-01-25Janssen Vaccines & Prevention B.V.Methods and compositions for inducing protective immunity against RSV infection
US11229695B2 (en)2017-09-152022-01-25Janssen Vaccines & Prevention B.V.Method for the safe induction of immunity against RSV
US11447566B2 (en)2018-01-042022-09-20Iconic Therapeutics, Inc.Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
US12215167B2 (en)2018-01-042025-02-04Iconic Therapeutics LlcAnti-tissue factor antibodies, antibody-drug conjugates, and related methods
US11911453B2 (en)2018-01-292024-02-27Modernatx, Inc.RSV RNA vaccines
US11771755B2 (en)2018-02-282023-10-03University Of WashingtonSelf-asssembling nanostructure vaccines
WO2019178521A1 (en)*2018-03-162019-09-19University Of Pittsburgh-Of The Commonwealth System Of Higher EducationCompositions and methods for vaccination against respiratory syncitial virus infection
US20210023195A1 (en)*2018-03-162021-01-28University Of Pittsburgh-Of The Commonwealth System Of Higher EducationCompositions and methods for vaccination against respiratory syncitial virus infection
US11623004B2 (en)*2018-03-162023-04-11University Of Pittsburgh Of The Commonwealth System Of Higher EducationCompositions and methods for vaccination against respiratory syncytial virus infection
US12331077B2 (en)2018-11-132025-06-17Janssen Vaccines & Prevention B.V.Stabilized pre-fusion RSV F proteins
US12098383B2 (en)2019-05-302024-09-24Gritstone Bio, Inc.Modified adenoviruses
US11591619B2 (en)2019-05-302023-02-28Gritstone Bio, Inc.Modified adenoviruses
US11771747B2 (en)2020-08-062023-10-03Gritstone Bio, Inc.Multiepitope vaccine cassettes
US20230310570A1 (en)*2020-08-172023-10-05University Of Pittsburgh-Of The Commonwealth System Of Higher EducationCompositions and methods for vaccination of juveniles againstrespiratory syncytial virus infection
CN118108812A (en)*2023-05-042024-05-31国药中生生物技术研究院有限公司 RSV F protein mutants
WO2025031486A1 (en)*2023-08-092025-02-13深圳瑞吉生物科技有限公司Respiratory syncytial virus antigenic polypeptide, vaccine, and use
CN117736278A (en)*2023-12-252024-03-22英诺特(唐山)生物技术有限公司Kit and detection method for detecting respiratory syncytial virus infection

Also Published As

Publication numberPublication date
BR112013029169B1 (en)2021-09-28
FR23C1046I2 (en)2025-01-03
ES2651143T3 (en)2018-01-24
AU2012255971A1 (en)2013-05-02
SMT201700569T1 (en)2018-01-11
BR112013029169A2 (en)2017-09-19
EP3275892A3 (en)2018-03-14
HUE048777T2 (en)2020-08-28
MX351011B (en)2017-09-28
EP2707385B1 (en)2017-09-20
CA2835644A1 (en)2012-11-22
US20250042951A1 (en)2025-02-06
FR23C1046I1 (en)2024-01-12
CY1119849T1 (en)2018-06-27
WO2012158613A1 (en)2012-11-22
HRP20171703T1 (en)2017-12-15
US20230287056A1 (en)2023-09-14
SI2707385T1 (en)2018-01-31
US20240239845A1 (en)2024-07-18
ES2782119T3 (en)2020-09-10
SI3275892T1 (en)2020-06-30
PL2707385T3 (en)2018-03-30
DK3275892T3 (en)2020-04-06
JP2014519819A (en)2014-08-21
PL3275892T3 (en)2020-09-07
US12139512B2 (en)2024-11-12
LT2707385T (en)2017-12-11
CA2835644C (en)2021-06-15
US20220332766A1 (en)2022-10-20
PT2707385T (en)2017-12-19
RS56748B1 (en)2018-03-30
RU2013155485A (en)2015-06-20
US20210269489A1 (en)2021-09-02
DK2707385T3 (en)2017-11-20
MX2013013133A (en)2014-02-20
EP2707385A1 (en)2014-03-19
HRP20200451T1 (en)2020-06-26
PT3275892T (en)2020-04-08
US20220332767A1 (en)2022-10-20
LT3275892T (en)2020-04-10
EP3275892B1 (en)2020-01-08
NO2707385T3 (en)2018-02-17
SG194755A1 (en)2013-12-30
EP3275892A2 (en)2018-01-31
CN103842374A (en)2014-06-04
HUE034673T2 (en)2018-02-28
US20180237476A1 (en)2018-08-23
CY1122826T1 (en)2021-05-05

Similar Documents

PublicationPublication DateTitle
US12139512B2 (en)Pre-fusion RSV F antigens
US11827694B2 (en)RSV F protein compositions and methods for making same

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:NOVARTIS AG, SWITZERLAND

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS, INC.;REEL/FRAME:031698/0326

Effective date:20131108

ASAssignment

Owner name:GLAXOSMITHKLINE BIOLOGICALS SA, BELGIUM

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS AG;REEL/FRAME:038982/0802

Effective date:20160615

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp